PureTech Health Celebrates FDA Approval of Cobenfy: A Milestone in Schizophrenia Treatment
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults.
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March of 2024. Royalty Pharma had acquired an interest in PureTech's royalty in KarXT.
PureTech Systems Inc., the leader in geospatial AI-boosted video analytics for wide-area perimeter and border security, is ...
Wall Street rose this afternoon after better than expected inflation figures cleared the way for the US Federal Reserve to ...
PureActiv will deploy across multiple locations to detect unauthorized access as ships travel through the waterway system.
Clinical-stage biotherapeutics company PureTech Health has announced that the schizophrenia treatment it developed, which was ...
Andrew Miller, then an executive at PureTech Health, licensed xanomeline in 2012 and founded Karuna to develop the treatment. Karuna solved the side effect problem by adding trospium, a muscarinic ...
The PureActiv enhancement automatically validates access control security violations and dismisses nuisance alarms.
Company car drivers will face a 32% benefit-in-kind (BiK) tax charge for the DS 4 PureTech, owing to its CO2 emissions of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback